Clinical Trial Update: Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating long-acting release octreotide in advanced hepatocellular carcinoma has completed; this update documents the evaluation of its effica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sandostatin LAR (octreotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Hepatocellular Carcinoma | Phase 3 | Status: COMPLETED